Sanofi India has accepted the resignation of its managing director (MD), Rajaram Narayanan, effective close of business hours on 10 April 2022.
As per the press release, "Rajaram has decided to pursue an opportunity outside of Sanofi. His successor will be appointed in due course."
Mr Rajaram Narayanan had joined the company in 2014 as General Manager and was later elevated to the position of country lead and managing director (MD). In these roles, Mr Narayanan had led the reorientation of the organisation, sharpening its focus on core areas, developing new business models, building future talent and driving digital transformation across all areas of the business.
Sanofi India also took significant steps to streamline its portfolio, supply footprint and go-to-market operations.
Sanofi India's net profit surged 298.64% to Rs 529.80 crore on a 9.88% rise in revenue from operations to Rs 754.50 crore in Q3 September 2021 over Q3 September 2020.
Sanofi India is one of the entities through which Sanofi operates in India. It offers a wide array of medicines for therapy areas such as diabetes, cardiology, thrombosis, central nervous system and anti-histamines. The products manufactured by the company are distributed in India and exported to many developed as well as developing countries.
Shares of Sanofi India rose 0.49% to Rs 7,571.15 on BSE. The announcemnt was made at the fag end of market hours yesterday, 13 January 2022.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU